Akeso Inc. (9926.HK) today announced that its proprietary next-generation humanized IgG4 monoclonal antibody targeting CD47, ...

Akeso Inc. (9926.HK) today announced that its proprietary next-generation humanized IgG4 monoclonal antibody targeting ...

The FDA granted orphan drug designation to ligufalimab for AML, reflecting its potential as an immune-based therapy that may ...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to the investigational therapy MNV-201 for the ...

Tamibarotene plus azacitidine for higher-risk myelodysplastic syndrome shows no added benefit in phase 3 trial.

FDA fast track is intended to expedite the development of therapies that fill serious unmet medical needs. With this ...

Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that ...

Researchers executed a phase 1b study to determine the safety and efficacy of venetoclax combined with a 7+3 chemotherapy regimen in treating acute myeloid leukemia.

A broad spectrum of systemic inflammatory manifestations defines VEXAS syndrome, with cutaneous, respiratory, and vascular ...